AMERICA'S HEALTH INSURANCE PLANS, INC. (AHIP) for AMERICA'S HEALTH INSURANCE PLANS INC (AHIP)
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
H.R. 1, American Recovery and Reinvestment Act (Obey) TAA health care tax credits; H.R. 897, Long-Term Care and Retirement Security Act (Putnam) tax incentives for LTC insurance; S. 94, Long-Term Care Family Accessibility Act (Vitter) tax incentives for LTC insurance; S. 702, Long-Term Care Affordability and Security Act (Grassley) tax incentives for LTC insurance (continued) TAX (Tax) Regulatory: Issues relating to Health Savings Accounts; issues related to COBRA subsidy requirements; and issues relating to withholding of government contract payments.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BEHRENDS FOSTER | — |
| KAREN IGNAGNI | — |
| ALETHIA JACKSON | — |
| SCOTT KEEFER | — |
| SCOTT STYLES | — |
| KELLY RENEA VOGEL | — |
| THOMAS JEROME WILDER | — |
| MARILYN ZIGMUND LUKE | — |
Health Issues HCR
H.Con.Res. 85 Budget Resolution (Spratt) health-related provisions; H.R. 1, American Recovery and Reinvestment Act (Obey) health information technology, privacy, comparative effectiveness research, prevention and wellness; H.R. 15, National Health Insurance Act (Dingell) single-payer health reform (continued) H.R. 109, America's Affordable Health Care Act (Fortenberg) essential benefits plan, high risk pools; H.R. 193, AmeriCare Health Care Act (Stark) new government health program; H.R. 544, Flexible Health Savings Act (Royce) FSA rollovers; H.R. 598, Economic Recovery Provisions (Rangel) health information technology, privacy; H.R. 629, Economic Recovery Provisions (Waxman) health information technology, privacy; H.R. 676, United States National Health Care Act (Conyers) single payer health reform; H.R. 679, Economic Recovery Provisions (Obey) health information technology, privacy, comparative effectiveness research, prevention and wellness; H.R. 1086, Help Efficient, Accessible, Low-cost, Timely Healthcare Act (Gingrey) medical liability reform; H.R. 1105, Omnibus Appropriations Act (Obey) high risk pools, comparative effectiveness research; H.R. 1200, American Health Security Act (McDermott) single-payer health reform; H.R. 1468, Medical Justice Act (Burgess) medical liability reform; H.R. 1493, Quality Health Care Coalition Act (Paul) antitrust exemption for physicians; H.R. 1658, Veterans Healthcare Commitment Act (Tiahrt) third party billing by VA for service-connected disabilities; H.R. 1721, CLASS Act (Pallone) national LTC program; S.Con.Res. 13 Budget Resolution (Conrad) health-related provisions; S. 45, Medical Care Access Protection Act (Ensign) medical liability reform; S. 179, Health Information Technology Act (Stabenow) health information technology; S. 336, Economic Recovery Provisions (Inouye) health information technology, privacy, comparative effectiveness research; S. 350, Economic Recovery Provisions (Baucus) health information technology; S. 697, CLASS Act (Kennedy) national LTC program; S. 698, State-Based Health Care Reform Act (Feingold) pilot projects for state-based health reforms; S. 703, American Health Security Act (Sanders) single-payer health reform HCR (Regulatory Issues): HIPAA administrative simplification issues, including standards for privacy, security, and electronic transactions and code sets; FEHBP enrollment data clearinghouse initiative; issues relating to health insurance plan participation in FEHBP, including contract requirements related to interoperability of health information technology, community rating policies, and similarly sized subscriber group (SSSG) requirement; implementation of the health savings account provisions of the Medicare Act; issues related to Medicare Secondary Payer requirements; issues related to implementation of the National Health Information Infrastructure; issues relating to market consolidation; issues relating to quality improvement; issues related to potential priority research topics for the effective health care program; issues related to provider conscience requirements; issues relating to the national health data stewardship; issues relating to hospital outpatient measurement and reporting; issues related to genetics and genetic nondiscrimination; and issues relating to Form 5500 reporting requirements.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY BACHER New | — |
| CARMELLA BOCCHINO | — |
| ELIZABETH BROOKS | — |
| JILL DOWELL | — |
| PAUL EITING | — |
| BEHRENDS FOSTER | — |
| LINDY HINMAN | — |
| KAREN IGNAGNI | — |
| ALETHIA JACKSON | — |
| SCOTT KEEFER | — |
| JEFF LEMIEUX | — |
| SUE ROHAN | — |
| CANDACE SCHALLER | — |
| SCOTT STYLES | — |
| JEANETTE THORNTON | — |
| ALLISON TURZA | — |
| KELLY RENEA VOGEL | — |
| THOMAS JEROME WILDER | — |
| DUANE WRIGHT | — |
| MARILYN ZIGMUND LUKE | — |
Medicare/Medicaid MMM
H.R. 1, American Recovery and Reinvestment Act (Obey) Medicaid FMAP; H.R. 2, Children's Health Insurance Program Reauthorization Act (Pallone) CHIP expansion; H.R. 629, Economic Recovery Provisions (Waxman) Medicaid FMAP, Medicaid option for unemployed; H.R. 684, Medicare Prescription Drug Savings and Choice Act (Berry) Part D reforms (continued) H.R. 904, Medicaid Prescription Drug Rebate Equalization Act (Stupak) Medicaid drug costs; H.R. 1407, Medicare Part D Home and Community Services Copayment Equity Act (Doggett) Part D cost sharing; H.R. 1670, Community Choice Act (Davis) Medicaid coverage; H.R. 1832, Medicare Prescription Drug Affordability Act (Wexler) Part D reforms; S.Con.Res. 13 Budget Resolution (Conrad) Medicare Advantage funding; S. 75, Generics First Act (Kohl) Part D reforms; S. 266, Medicare Prescription Drug Gap Reduction Act (Nelson) Part D reforms; S. 275, Children's Health Insurance Program Reauthorization Act (Baucus) CHIP expansion; S. 330, Medicare Prescription Drug Savings and Choice Act (Durbin) Part D reforms; S. 350, Economic Recovery Provisions (Baucus) Medicaid FMAP; S. 534, Home and Community Services Copayment Equity Act (Nelson) Part D reforms; S. 547, Drug Rebate Equalization Act (Bingaman) Medicaid drug costs; S. 677, REPAIR Act (Ensign) means-testing Part D premiums; S. 683, Community Choice Act (Harkin) Medicaid coverage MMM (Regulatory Issues) Ongoing implementation issues for the Medicare Advantage (MA) and Medicare Part D prescription drug programs, including risk adjustment methodology and data issues, (including audit and encounter data issues), bidding and payment issues (including MA rate assumptions, MA coding intensity, Part D reinsurance, Part D low income subsidies, and audits), application process, audits to evaluate compliance with MA and Part D program rules, benefit design rules, SSA and CMS premium withhold processing issues, enrollment rules, marketing materials review and approval, marketing activities, including conduct and compensation of brokers and agents and plan sponsor marketing staff, measurement and oversight of plan performance including Special Needs Plans (SNPs); quality measures, grievance and appeals processes, compliance/fraud and abuse training, and Medicare/Medicaid integration issues for Special Needs Plans (SNPs); Federal preemption of State authority under MA and Part D programs, Part D prescription drug event data reporting, Part D formulary rules, Part D pharmacy access standards, and other operational issues; Medicare creditable drug coverage reporting requirements; implementation issues for the Medicare Retiree Drug Subsidy program; functionality of the Medicare Personal Plan Finder and Drug Plan Finder; National Medicare Education program; ongoing implementation issues for the Medicare cost plan program including enrollment, marketing materials review and approval and other operational issues, MA and Part D systems issues affecting enrollment and disenrollment processing and payment and other operational issues; Medicare demonstration program on performance-based payments for physician groups; physician quality reporting initiative; issues relating to Medicare coverage policy and national coverage decisions; Medicare clinical trials; Medicaid managed care regulations and policies, including the Medicaid managed care actuarial soundness standard, quality oversight, grievance and appeals processes, beneficiary information requirements, treatment of Medicaid health plan member hospital days in the upper payment limit calculation; policies affecting State Medicaid funding, including intergovernmental transfers (IGTs); coordination of benefits with state Medicaid programs; Medicaid prescription drug cost/rebate issues affecting Medicaid health plans; health plan-related State Childrens Health Insurance Program (SCHIP) issues, including eligibility and outreach issues; implementation of Medicaid changes made in Deficit Reduction Act of 2005, including documentation of citizenship requirements, state benefit flexibility options, and Medicaid managed care organization provider tax issues; standards for electronic prescribing; and health information technology standards and policies.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARMELLA BOCCHINO | — |
| JILL DOWELL | — |
| BEHRENDS FOSTER | — |
| KAREN IGNAGNI | — |
| ALETHIA JACKSON | — |
| JEFF LEMIEUX | — |
| SUE ROHAN | — |
| CANDACE SCHALLER | — |
| SCOTT STYLES | — |
| KELLY RENEA VOGEL | — |
| HOWARD WEISS | — |
| THOMAS JEROME WILDER | — |
| DUANE WRIGHT | — |
Insurance INS
H.R. 1, American Recovery and Reinvestment Act (Obey) COBRA; H.R. 323, Comprehensive Insurance Coverage of Childhood Immunization Act (Green) immunization coverage mandate; H.R. 584, Menopausal Hormone Replacement Therapies and Alternative Treatments and Fairness Act (Lee) coverage mandate for hormone replacement therapy; H.R. 598, Economic Recovery Provisions (Rangel) COBRA (continued) H.R. 629, Economic Recovery Provisions (Waxman) COBRA; H.R. 697, Family Building Act (Weiner) coverage mandate for infertility treatments; H.R. 716, Access to Cancer Clinical Trials Act (Israel) clinical trials coverage mandate; H.R. 850, Small Business CHOICE Act (Velazquez) small employer health options; H.R. 859, Small Business CHOICE Act (Velazquez) small employer health options; H.R. 995, Mammogram and MRI Availability Act (Nadler) coverage mandate for mammograms; H.R. 1085, Health Insurance Coverage Protection Act (Eshoo) lifetime benefit limits; H.R. 1092, No Discrimination in Health Insurance Act (Kagen) preexisting condition exclusions, affiliation periods, uniform premiums; H.R. 1253, Health Insurance Restrictions and Limitations Clarification Act (Burgess) disclosure of coverage exclusions; H.R. 1321, Healthy Americans Act (Eshoo) comprehensive health reform; H.R. 1330, Colorectal Cancer Screening and Detection Coverage Act (Boren) coverage mandate for cancer screening; H.R. 1339, Children's Access to Reconstructive Evaluation & Surgery Act (McCarthy) coverage mandate for treatment of a child's congenital or developmental deformity; H.R. 1558, Preexisting Condition Patient Protection Act (Courtney) preexisting condition exclusions; H.R. 1583, Insurance Industry Competition Act (DeFazio) McCarran Ferguson reforms; H.R. 1619, Children's Health Protection Act (Schwartz) preexisting condition exclusions for children; H.R. 1691, Breast Cancer Patient Protection Act (DeLauro) rescissions, hospital stays for breast cancer patients; S. 79, Healthy Businesses, Healthy Workers Reinsurance Act (Kerry) reinsurance; S. 93, Small Business Empowerment Act (Brown) small employer health options; S. 350, Economic Recovery Provisions (Baucus) COBRA; S. 391, Healthy Americans Act (Wyden) comprehensive health reform; S. 442, Health Insurance Coverage Protection Act (Dorgan) lifetime benefit limits; S. 488, Access to Cancer Clinical Trials Act (Brown) clinical trials coverage mandate; S. 623, Pre-existing Condition Patient Protection Act (Rockefeller) preexisting condition exclusions; S. 643, Children's Health Protection Act (Lautenberg) preexisting condition exclusions for children; S. 688, Breast Cancer Patient Protection Act (Snowe) rescissions, hospital stays for breast cancer patients INS (Regulatory) Insurance regulatory reform; issues related to the coordination of private and public disability income benefits; disability risk management; issues relating to the coordination of benefits between private health insurance plans and Medicaid; crossover fees for Medigap claims; Medigap carrier recoveries related to CMS fraud and abuse enforcement activities, and issues related to Medigap educational materials; implementation of the Mental Health Parity Act requirements; issues related to COBRA subsidy requirements, and issues related to genetic nondiscrimination.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GARY BACHER New | — |
| CARMELLA BOCCHINO | — |
| ELIZABETH BROOKS | — |
| JILL DOWELL | — |
| PAUL EITING | — |
| BEHRENDS FOSTER | — |
| LINDY HINMAN | — |
| KAREN IGNAGNI | — |
| ALETHIA JACKSON | — |
| SCOTT KEEFER | — |
| JEFF LEMIEUX | — |
| SUE ROHAN | — |
| CANDACE SCHALLER | — |
| SCOTT STYLES | — |
| JEANETTE THORNTON | — |
| ALLISON TURZA | — |
| KELLY RENEA VOGEL | — |
| THOMAS JEROME WILDER | — |
| DUANE WRIGHT | — |
| MARILYN ZIGMUND LUKE | — |
Pharmacy PHA
H.R. 1204, Community Pharmacy Fairness Act (Weiner) antitrust exemption for pharmacies; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act (Waxman) generic biologics; H.R. 1548, Pathway for Biosimilars Act (Eshoo) generic biologics (continued) H.R. 1706, Protecting Consumer Access to Generic Drugs Act (Rush) generic drugs; S. 369, Preserve Access to Affordable Generics Act (Kohl) generic drugs; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act (Schumer) generic biologics PHA (Regulatory): Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; and issues relating to access for investigational drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARMELLA BOCCHINO | — |
| JILL DOWELL | — |
| BEHRENDS FOSTER | — |
| KAREN IGNAGNI | — |
| ALETHIA JACKSON | — |
| CANDACE SCHALLER | — |
| SCOTT STYLES | — |
| KELLY RENEA VOGEL | — |
| HOWARD WEISS | — |
| THOMAS JEROME WILDER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.